Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Thalidomide
Drug: TAS-102

First Posted Date: 2022-03-04

Last Posted Date: 2022-03-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT05266820

Locations: 🇨🇳
First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳
Fuzhou First Hospital affiliated to Fujian Medical University, Fuzhou, China
🇨🇳
The Third People's Hospital affiliated to Fujian University of Chinese Medicine, Fuzhou, China

and more 3 locations

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Immunotherapy
Gastrict Cancer

Interventions: Drug: Tislelizumab
Drug: Apatinib Mesylate
Drug: oxaliplatin
Drug: Tegafur

First Posted Date: 2022-02-03

Last Posted Date: 2023-01-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT05223088

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, China

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Phase 2

Conditions: Advanced Non-small-cell Lung Cancer

Interventions: Drug: Tislelizumab

First Posted Date: 2022-01-14

Last Posted Date: 2022-01-14

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 35

Registration Number: NCT05192681

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China

the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer

Not Applicable

Conditions: Colorectal Cancer Stage III
Colorectal Cancer Stage II

Interventions: Procedure: Chemotherapy time

First Posted Date: 2021-11-23

Last Posted Date: 2021-11-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT05131243

Effects of Mobile Medicine on Cancer Patients

Not Applicable

Conditions: Cancer Pain

Interventions: Behavioral: mini program
Behavioral: conventional pharmaceutical care

First Posted Date: 2021-09-20

Last Posted Date: 2021-09-21

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT05049811

Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer

Phase 3

Conditions: Surgery

Interventions: Procedure: conventional laparoscopic surgery
Procedure: single-incision plus one-port laparoscopic surgery

First Posted Date: 2021-09-05

Last Posted Date: 2021-10-11

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT05035446

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Phase 1

Conditions: Advanced Triple Negative Breast Cancer

Interventions: Drug: Apatinib Mesylate
Drug: Albumin-Bound Paclitaxel

First Posted Date: 2021-08-25

Last Posted Date: 2021-08-25

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05019690

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Neoplasms
Esophageal Squamous Cell Carcinoma

Interventions: Drug: Albumin-Bound Paclitaxel
Drug: PD-1 inhibitor
Drug: Cisplatin
Radiation: Radiation

First Posted Date: 2021-08-16

Last Posted Date: 2021-12-21

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 92

Registration Number: NCT05007145

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
the Second Hospital of Longyan, Longyan, Fujian, China
🇨🇳
the First Hospital of Putian City, Putian, Fujian, China

and more 3 locations

Study of FMT Combined With Nivolumab in Gastric Cancer

Not Applicable

Withdrawn

Conditions: Esophagogastric Junction Adenocarcinoma
Esophagus Adenocarcinoma
Gastric Adenocarcinoma

Interventions: Drug: XBI-302 + Nivolumab

First Posted Date: 2021-08-11

Last Posted Date: 2021-10-27

Lead Sponsor: Fujian Cancer Hospital

Registration Number: NCT05001360

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Surufatinib(HMPL-012)

First Posted Date: 2021-07-09

Last Posted Date: 2021-07-09

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 14

Registration Number: NCT04955886

Locations: 🇨🇳
Affiliated Cancer Hospital of Sun Yat-sen University, Guangdong, China
🇨🇳
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy